Hikma Pharmaceuticals (LON:HIK) Share Price Crosses Below 50 Day Moving Average After Analyst Downgrade

Hikma Pharmaceuticals PLC (LON:HIK) crossed below its 50 day moving average during trading on Monday after Berenberg Bank lowered their price target on the stock from GBX 2,100 to GBX 2,050. The stock has a 50 day moving average of GBX 1,628.07 and traded as low as GBX 1,625. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals shares last traded at GBX 1,625, with a volume of 1,570,051 shares trading hands.

Several other brokerages have also recently commented on HIK. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Hikma Pharmaceuticals from GBX 2,050 to GBX 2,000 and set a “buy” rating for the company in a report on Friday. Jefferies Financial Group restated a “buy” rating and set a GBX 2,025 price target on shares of Hikma Pharmaceuticals in a report on Thursday. Finally, Citigroup boosted their price target on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a report on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of GBX 1,986.25.

Hikma Pharmaceuticals Stock Performance

The firm has a 50-day simple moving average of GBX 1,628.07 and a two-hundred day simple moving average of GBX 1,509.46. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The company has a market capitalization of £3.36 billion, a price-to-earnings ratio of 9.23, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.